AnaptysBio (ANAB) Projected to Post Quarterly Earnings on Wednesday

AnaptysBio (NASDAQ:ANAB) is anticipated to announce its Q2 2026 results before the market opens on Wednesday, August 5th. Analysts expect AnaptysBio to post earnings of ($0.1252) per share and revenue of $17.3340 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, August 13, 2026 at 4:00 PM ET.

AnaptysBio (NASDAQ:ANAB) last announced its earnings results on Tuesday, May 12th. The biotechnology company reported ($1.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.64) by ($1.20). The business had revenue of $25.56 million during the quarter, compared to analyst estimates of $18.86 million. On average, analysts expect AnaptysBio to post $-1 EPS for the current fiscal year and $3 EPS for the next fiscal year.

AnaptysBio Price Performance

AnaptysBio stock opened at $53.36 on Monday. The business has a 50-day simple moving average of $57.73 and a two-hundred day simple moving average of $57.85. AnaptysBio has a 52-week low of $11.40 and a 52-week high of $72.36. The company has a market cap of $1.58 billion, a P/E ratio of -49.41 and a beta of 0.72.

Institutional Trading of AnaptysBio

Institutional investors and hedge funds have recently modified their holdings of the company. Invesco Ltd. raised its position in shares of AnaptysBio by 192.6% during the 4th quarter. Invesco Ltd. now owns 124,006 shares of the biotechnology company’s stock valued at $6,012,000 after purchasing an additional 81,625 shares during the period. Mackenzie Financial Corp bought a new position in AnaptysBio in the 4th quarter worth $1,166,000. XTX Topco Ltd increased its stake in AnaptysBio by 113.3% in the 4th quarter. XTX Topco Ltd now owns 38,637 shares of the biotechnology company’s stock worth $1,873,000 after buying an additional 20,526 shares in the last quarter. nVerses Capital LLC purchased a new stake in AnaptysBio in the 4th quarter worth $215,000. Finally, Voloridge Investment Management LLC raised its holdings in AnaptysBio by 2,358.3% during the fourth quarter. Voloridge Investment Management LLC now owns 229,137 shares of the biotechnology company’s stock valued at $11,109,000 after acquiring an additional 219,816 shares during the period.

Analyst Ratings Changes

Several analysts recently issued reports on the stock. Weiss Ratings lowered shares of AnaptysBio from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, May 13th. Wall Street Zen cut AnaptysBio from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 16th. Piper Sandler decreased their target price on AnaptysBio from $95.00 to $93.00 and set an “overweight” rating on the stock in a report on Monday, May 4th. Leerink Partners set a $90.00 target price on AnaptysBio in a research report on Friday, May 15th. Finally, HC Wainwright started coverage on AnaptysBio in a report on Wednesday, June 10th. They set a “buy” rating and a $95.00 price target for the company. Nine equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $82.00.

About AnaptysBio

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.